\n<\/p>\n
There\u2019s no denying the results as Clene revolutionizes the treatment of neurodegenerative disease<\/em><\/p>\n Seven-figure funding has obvious financial benefits for any business. When it comes from a government entity, however, it also represents confidence that the company is doing something to benefit the community and has a high chance of succeeding.<\/p>\n This is definitely the case with Salt Lake City-based Clene Inc. (CLNN). This biopharmaceutical business addresses significant market opportunities: amyotrophic lateral sclerosis (ALS), a market valued at<\/a> $1 billion globally by 2029; multiple sclerosis (MS), valued at $23 billion; and Parkinson\u2019s disease, valued at $6 billion by 2026.<\/p>\n But of course, this isn\u2019t just a cash grab by any means. In fact, Clene seeks to improve upon the prevailing treatment modalities for neurodegenerative disease with an innovative nano-therapeutic platform.<\/p>\n A highly promising ALS treatment candidate could be life-changing, and there\u2019s recent data demonstrating excellent progress. At the same time, a big-dollar financial award proves that Clene Inc. is a worthy investment in the future of life-changing medicine.<\/p>\n A Closer Look at CLNN Stock<\/strong><\/p>\n Let me tell you, when CLNN stock runs, it runs hot and fast. You definitely don\u2019t want to be on the short side of the trade \u2013 that\u2019s for sure.<\/p>\n I remember when CLNN stock was trading at $6 and change in late January of 2021. Any short sellers would soon get a smack-down, and probably had to cover their positions lest they get a margin call from their brokers.<\/p>\n Astoundingly, in February CLNN stock shot up to $17.82 \u2013 I told you, hot and fast! A similar rally occurred from May to mid-July, when the stock soared from $6 and change to $14.<\/p>\n Clearly, this is a stock that can be a multi-bagger if you buy it at the right price. So, is it time to re-load and prepare for the next boom cycle?<\/p>\n The answer is certainly in the affirmative, as CLNN stock recently pulled back to $5 and change. It\u2019s basically an open door, just waiting for attentive investors to take a position before the crowd of buyers come rushing in again.<\/p>\n Encouraging Results<\/strong><\/p>\n The battle against ALS seems like it\u2019s never-ending \u2013 it\u2019s always a challenge.<\/p>\n Yet, Clene Inc.\u2019s recently reported clinical data should offer hope and encouragement to ALS patients.<\/p>\n The company\u2019s lead drug candidate, CNM-Au8, is an oral suspension of gold nano-crystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neuro-repair and improve neuro-protection.\u00a0<\/p>\n CNM-Au8 is currently being evaluated in a Phase 3 registration trial in ALS as well as a Phase 2 trial for the treatment of chronic optic neuropathy in patients with stable relapsing MS.<\/p>\n Clene has been aggressively advancing RESCUE-ALS, a Phase 2 clinical trial to evaluate CNM-Au8 as a disease-modifying treatment for people with early ALS.<\/p>\n Among other results, RESCUE-ALS showed<\/a> evidence for a potential long-term survival benefit from CNM-Au8 when comparing the observed survival of the trial population to the predicted survival, based on the validated ENCALS model.<\/p>\n